Table 1 Patient backgrounds

Aminoglycosides

Amikacin

47

59

Gentamicin

46

54

Tobramycin

21

24

Arbekacin

9

3

Characteristics

Male

80

93

Age, years

69 (13)

68 (15)

Pre-aminoglycosides administration test values

Weight (kg)

53.6 (11.6)

53.8 (14.0)

Body mass index (kg/m²)

21.1 (4.3)

20.9 (4.5)

Creatinine (mg/dL)

0.75 (0.53)

0.92 (0.85)

eGFR (mL/min/1.73 m²)

78.5 (23.3)

73.1 (24.7)

Focus of infection

Endocarditis

34

36

Pneumonia

14

33

Skin and soft tissue

29

22

Febrile neutropenia

16

18

Others

28

26

Unknown

2

5

Pathogens*

Gram-positive cocci

32

48

 Streptococcus spp.

12

27

 Staphylococcus spp.

8

14

 Enterococcus spp.

9

6

 Others

3

1

Gram-negative rods

30

43

 Pseudomonas aeruginosa (Carbapenem resistant)

16

28

 Pseudomonas aeruginosa (Carbapenem susceptible)

8

5

 Enterobacterales (ESBLs)

2

4

 Enterobacterales (non-ESBLs)

4

6

NTM

6

15

Others

2

1

Not detected

51

35

Multiple bacteria targeted

3

3

Aminoglycosides treatment duration

13 (10)

13 (9)